orlistat · Xenical

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Obesity

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Weak signal

Also approved (1)
EU
  • Xenical (orlistat 120 mg), treatment of obese patients (BMI >= 30) or overweight patients (BMI > 28) with associated risk factors, with a mildly hypocaloric diet
Product first approved 1998EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (4)
Obesity
NCT02432209 · Yale University
2015-08 – 2020-05 · Infertility, Female
What this study did
NCT01755676 · EMS
2016-09 – 2017-12-21 · Obesity
What this study did
NCT01047657 · University of Sao Paulo General Hospital
2009-11 – 2010-12 · Asthma, Obesity, Weight Loss
What this study did
Phase 2 (12)
Obesity
NCT06993428 · Empros Pharma AB
2025-05-20 – 2025-07-29 · Overweight or Obese, Obesity and Overweight
What this study did
NCT02069197 · Mid-Atlantic Epilepsy and Sleep Center, LLC
2014-01 – 2020-09 · Obesity, Diabetes, Obstructive Sleep Apnea
What this study did
NCT01351753 · University of Iowa
2011-03 – 2014-01-09 · Obesity, Metabolic Syndrome X
What this study did
NCT00001723 · Jack Yanovski
1998-05 – 2011-10 · Diabetes Mellitus, Hypertension, Metabolic Disease, Obesity, Sleep Apnea Syndrome
What this study did
NCT01003483 · Yazd Research & Clinical Center for Infertility
2008-12-01 – 2009-11 · Obesity
What this study did
NCT00156897 · Alizyme
2004-12 – 2005-10 · Non-Insulin-Dependent Diabetes Mellitus, Obesity
What this study did
Other / comorbidity
NCT07714070 · Peking University People's Hospital
2026-07 – 2029-12 · Endometrial Neoplasms, Endometrial Cancer, Atypical Endometrial Hyperplasia, Progestin Resistance
What this study did
NCT05816343 · University of Texas Southwestern Medical Center
2024-01-26 – 2029-05-30 · Type 1 Hyperlipoprotenemia
What this study did
NCT06818955 · Ping Peng
2025-02-16 – 2025-11-15 · Lung Adenocarcinoma, Osimertinib
What this study did
NCT02767531 · University of Texas Southwestern Medical Center
2015-12 – 2022-12-31 · Hyperlipoproteinemia Type I, Hypertriglyceridemia
What this study did
NCT01675154 · University of Texas Southwestern Medical Center
2015-11 – 2020-06-30 · Type 1 Hyperlipoproteinemia
What this study did
NCT00704912 · Milton S. Hershey Medical Center
2008-09 – 2014-03 · Polycystic Ovary Syndrome
What this study did
Phase 1 (2)
Obesity
NCT06013163 · Empros Pharma AB
2023-09-22 – 2024-12 · Overweight or Obesity
What this study did
Other / comorbidity
NCT05760677 · Affiliated Hospital of Nantong University
2022-10-01 – 2024-09-30 · PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries, T2D
What this study did
Phase 4 (16)
Obesity
NCT07301437 · The Fourth Affiliated Hospital of Zhejiang University School of Medicine
2026-05-01 – 2027-08-31 · Overweight and Obese Adults
What this study did
NCT05496075 · Shanghai 10th People's Hospital
2022-08-26 – 2023-12-01 · Uric Acid
What this study did
NCT04531176 · The Cleveland Clinic
2020-09-01 – 2023-08-04 · Type 2 Diabetes, Obesity
What this study did
NCT03582722 · Emory University
2018-09-14 – 2022-06-30 · Polybrominated Biphenyl Poisoning
What this study did
NCT00152360 · University of British Columbia
2005-06 – 2013-03 · Obesity, Heart Diseases
What this study did
NCT01475019 · Aristotle University Of Thessaloniki
2004-01 – 2012-12 · Obesity, Polycystic Ovaries Syndrome
What this study did
NCT01035333 · Albany College of Pharmacy and Health Sciences
2009-11 – 2011-04 · Obesity
What this study did
NCT00516919 · Yale University
2007-08 – 2010-12 · Obesity, Binge Eating
What this study did
NCT02706067 · Hoffmann-La Roche
2002-07 – 2009-03 · Obesity
What this study did
NCT00115063 · Pennington Biomedical Research Center
2005-07 – 2008-01 · Obesity
What this study did
NCT00160407 · St. Louis University
2003-10 – 2006-12 · Fatty Liver, Hepatitis
What this study did
NCT00212199 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2002-01 – 2004-08 · 1. Obesity
What this study did
Other / comorbidity
NCT02041234 · Khoo Teck Puat Hospital
2014-02 – 2022-06 · Type II Diabetes in Subjects BMI 27 to 32
What this study did
NCT03383068 · RenJi Hospital
2018-01-01 – 2020-06-30 · PCOS, Impaired Glucose Tolerance
What this study did
NCT01597531 · East Carolina University
2012-06 – 2014-06 · Type 2 Diabetes, Gastric Banding
What this study did
NCT00207311 · Brooke Army Medical Center
2005-08 – 2009-05 · Fatty Liver, Hepatitis C
What this study did
Early phase / not applicable (15)
Obesity
NCT07326839 · XueMei Guo
2025-12-10 – 2027-11-09 · Gout, Obesity
What this study did
NCT03675191 · Gangnam Severance Hospital
2018-10-16 – 2019-08-12 · Obesity, Overweight
What this study did
NCT00829283 · Yale University
2008-11 – 2013-11 · Obesity, Binge Eating
What this study did
NCT02529631 · Certmedica International GmbH
2009-11 – 2013-08 · Overweight, Obesity
What this study did
NCT01797757 · Société des Produits Nestlé (SPN)
2012-01 – 2012-12 · Obesity
What this study did
NCT01719419 · Pennington Biomedical Research Center
2012-03 – 2012-09 · Overweight
What this study did
NCT01320228 · University of Copenhagen
2011-04 – 2012-06 · Obesity
What this study did
NCT01414465 · University of Campinas, Brazil
2009-10 – 2011-06 · Overweight
What this study did
NCT01184560 · Gachon University Gil Medical Center
2010-02 – 2010-07 · Obesity
What this study did
NCT01170806 · University of Campinas, Brazil
2009-10 – 2010-04 · Obesity
What this study did
NCT00292799 · Sheffield Teaching Hospitals NHS Foundation Trust
2006-02 – 2008-02 · Anovulation, Obesity
What this study did
Other / comorbidity
NCT07747909 · Khyber Medical University Peshawar
2026-01-01 – 2026-09-15 · Polycystic Ovary Syndrome
What this study did
NCT05076474 · Shandong New Time Pharmaceutical Co., LTD
2020-10-01 – 2021-03-31 · Bioequivalence
What this study did
NCT00794963 · Northwell Health
2008-11 – 2010-05 · Metabolic Syndrome
What this study did
NCT00461799 · University Medical Center Groningen
2003-09 – 2004-01 · Crigler-Najjar Syndrome
What this study did
Used as active comparator (8)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 2 (3)
Obesity
NCT05934110 · Empros Pharma AB
2023-04-18 – 2024-03-15 · Overweight or Obesity
What this study did
NCT00422058 · Novo Nordisk A/S
2007-01-10 – 2009-04-30 · Metabolism and Nutrition Disorder, Obesity
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT02503865 · Nazarbayev University
2003-01 – 2014-12 · Metabolic Syndrome
What this study did
Phase 4 (2)
Obesity
NCT06501326 · Affiliated Hospital of Nantong University
2023-11-01 – 2025-02-28 · Non-alcoholic Fatty Liver Disease, Obesity
What this study did
NCT05579249 · Novo Nordisk A/S
2023-01-19 – 2024-11-27 · Obesity
What this study did
Early phase / not applicable (2)
Obesity
NCT06625736 · October 6 University
2024-01-05 – 2024-09-07 · Obese Women, Perimenopause
What this study did
NCT00108524 · US Department of Veterans Affairs
2004-07 – 2007-12 · Diabetes Mellitus, Obesity
What this study did
Studied as part of a combination product (1)

Studies of a fixed-dose combination that contains this drug. The combination is the product under test, so these are that product's evidence rather than this one's; the link is kept because the drug really was administered.

Phase 1/2 (1)
Obesity
NCT04521751 · Empros Pharma AB
2020-05-07 – 2021-08-30 · Overweight or Obesity
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Early phase / not applicable (1)
Obesity
NCT00601354 · Stanford University
2007-09 – 2008-12 · Overweight, Eating Disorders
What this study did

Competitive landscape

This drug's own stage for Obesity: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Orlistat (Xenical): this drugApprovedSmall moleculePancreatic/gastric lipaseWeak signalNo reviewed efficacy summary in this indication
Liraglutide (Saxenda)ApprovedPeptideGLP-1 receptorReliable signal
NCT02918279: Change in BMI SDS (Week 0, Week 56) (Week 0, week 56): Liraglutide 3.0 mg -0.25 SDS score (Standard Deviation 0.51) vs Placebo -0.02 SDS score (Standard Deviation 0.54)
NCT01557166: Change From Baseline in Apnoea-hypopnoea Index (AHI) (Week 0, Week 32): Liraglutide 3.0 mg -12.22 events/hour (Standard Deviation 23.34) vs Placebo -6.08 events/hour (Standard Deviation 25.9)
Naltrexone / Bupropion (Contrave)ApprovedSmall moleculeOpioid receptor / dopamine (combination), Dopamine/norepinephrine transporternot yet graded
NCT03374956: Change in Total Body Weight (baseline to 12 weeks): Intervention Group -7.7% (IQR -11 to -4.7) vs Control Group -6.5% (IQR -11 to -2.3) phase 3 result · pivotal pending
Orforglipron (Foundayo)ApprovedSmall moleculeGLP-1 receptorPartial signal
NCT05872620: Body weight change from baseline to Week 72 (treatment-regimen estimand): -9.6% orforglipron 17.2 mg vs -2.5% placebo (p<.001 for all orforglipron doses vs placebo); HbA1c change: -1.66% (17.2 mg) vs -0.47% placebo (p<.001)
NCT05803421: Primary endpoint, time to first MACE-4 (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke or hospitalisation for unstable angina), non-inferiority with margin 1.8 on the upper 95% CI bound of the hazard ratio: 57/1358 (4.2%) orforglipron vs 67/1343 (5.0%) insulin glargine; HR 0.84 (95% CI 0.59 to 1.20; p<0.0001 for non-inferiority), met.
Phentermine / Topiramate (Qsymia)ApprovedSmall moleculeNoradrenergic/anticonvulsant (combination)Reliable signal
NCT00553787: Percent Weight Loss From Baseline to Week 56 (Baseline to 56 weeks): VI-0521 Mid 7.81% (Standard Error 0.365) | VI-0521 Top 9.84% (Standard Error 0.275) vs Placebo 1.24% (Standard Error 0.277)
NCT00554216: Percent Weight Loss From Baseline to Week 56 (baseline to 56 weeks): VI-0521 Low 5.1% (Standard Error 0.538) | VI-0521 Top 10.92% (Standard Error 0.392) vs Placebo 1.55% (Standard Error 0.395)
Semaglutide (Wegovy Tablets)ApprovedPeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Semaglutide (Wegovy)ApprovedPeptideGLP-1 receptorReliable signal
NCT03574597: Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke (From randomisation (week 0) up to 240 weeks): Semaglutide 569/8803 vs Placebo 701/8801
NCT03548935: Change in Body Weight (%) (Baseline (week 0) to week 68): Semaglutide 2.4 mg — In-trial observation period: -15.6% (Standard Deviation 10.1); On-treatment observation period: -16.9% (Standard Deviation 9.4) vs Placebo — In-trial observation period: -2.8% (Standard Deviation 6.5); On-treatment observation period: -3.1% (Standard Deviation 6.4)
Setmelanotide (Imcivree)ApprovedPeptideMC4RWeak signal
NCT05774756: Pivotal Cohort: Mean Percent Change From Baseline in Body Mass Index (BMI) After 52 Weeks on a Therapeutic Regimen (Baseline, after approximately 52 Weeks on a Therapeutic Regimen (up to approximately 60 weeks)): Setmelanotide -16.51 Percent change (Standard Error 1.401) | Placebo 3.32 Percent change (Standard Error 1.984)
NCT03287960: Percentage of Participants Who Reached ≥10% Weight Loss Threshold After 1 Year (Pivotal Cohort) (Week 52): Setmelanotide (Entire Study) 45.5% (95% CI 19.96 to 72.88)
Tirzepatide (Zepbound)ApprovedPeptideGLP-1/GIP receptor (dual)Reliable signal
NCT05412004: Change From Baseline in Apnea-Hypopnea Index (AHI) (Baseline, Week 52): Tirzepatide MTD_GPI1 -25.25 events per hour (Standard Error 2.06) | Placebo_GPI1 -5.25 events per hour (Standard Error 2.11) | Tirzepatide MTD_GPI2 -29.27 events per hour (Standard Error 1.99) | Placebo_GPI2 -5.51 events per hour (Standard Error 2.21)
NCT04660643: Percent Change From Randomization in Body Weight at Week 88 (Randomization (Week 36), Week 88): Tirzepatide MTD -6.7 percent change (Standard Error 0.52) vs Placebo 14.8 percent change (Standard Error 0.53)
AleniglipronPhase 3Small moleculeGLP-1 receptorPartial signal
NCT06703021: Placebo-adjusted mean weight loss 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks (both p<0.0001)
ASC30Phase 3Small moleculeGLP-1 receptorPartial signal
NCT07002905: Placebo-adjusted mean weight loss at Week 13: 5.4% (20mg), 7.0% (40mg), 7.7% (60mg) ASC30, all p<0.0001 vs placebo
BerobenatidePhase 3PeptideGLP-1 receptorPartial signal
NCT06712836: Percent change in body weight at week 28 (Part A): berobenatide 0.4, 0.6, 0.9 and 1.2 mg weekly -6.41%, -8.36%, -11.29% and -12.45% vs placebo +1.67%; placebo-adjusted -8.09% to -14.13%, all p<0.0001 (CT.gov posted results).
BGM0504Phase 3PeptideGLP-1/GIP receptor (dual)Partial signal
NCT06973681: Placebo-adjusted LS-mean body weight reductions of 10.77% to 19.78% across BGM0504 dose groups (120 Chinese adults with obesity)
BofanglutidePhase 3PeptideGLP-1 receptorPartial signalNo reviewed efficacy summary in this indication
CagrilintidePhase 3PeptideAmylin receptor, Amylin/calcitonin receptor (dual)Reliable signal
NCT03856047: Change in Body Weight (%) (From baseline (week 0) to week 26): Cagrilintide 0.3 mg -6.1% (Standard Deviation 3.9) | Cagrilintide 0.6 mg -6.9% (Standard Deviation 5.4) | Cagrilintide 1.2 mg -8.5% (Standard Deviation 5.4) | Cagrilintide 2.4 mg -9.5% (Standard Deviation 6.2) | Cagrilintide 4.5 mg -10.8% (Standard Deviation 5.5) vs Liraglutide 3.0 mg -8.5% (Standard Deviation 5.6) | Pooled Placebo -3% (Standard Deviation 5.2)
Cagrilintide / Semaglutide (CagriSema)Phase 3PeptideAmylin receptor, GLP-1 receptor, Amylin/calcitonin receptor (dual)Reliable signal
NCT05394519: Change in body weight at week 68: -13.7% with CagriSema vs -3.4% with placebo; estimated difference -10.4 percentage points (p<0.001)
NCT05813925: Change in body weight at week 68: -18.4% (SE 0.7) CagriSema vs -11.9% (SE 0.7) semaglutide alone; ETD -6.5 percentage points (95% CI -8.4 to -4.6; p<0.0001)
DA-302168SPhase 3Small moleculeGLP-1 receptorPartial signalNo reviewed efficacy summary in this indication
EcnoglutidePhase 3PeptideGLP-1 receptorReliable signal
NCT05813795: Co-primary 1, percent change in body weight from baseline to week 40 (treatment-policy estimand): ecnoglutide 1.2 mg -9.1%, 1.8 mg -10.9%, 2.4 mg -13.2% vs placebo +0.1%; treatment differences -9.2% (97% CI -11.0 to -7.5), -11.1% (-13.1 to -9.1) and -13.3% (-15.3 to -11.3); all p<0.0001, met. Co-primary 2, weight reduction of at least 5% at week 40: 77%, 84% and 87% vs 16%; differences 60% (98% CI 50 to 71), 68% (58 to 78) and 70% (61 to 80); all p<0.0001, met.
Efmedaglutide Alfa (Shanmeining)Phase 3Protein / enzyme therapeuticGLP-1 receptorPartial signal
NCT05997576: Body weight vs placebo in overweight or obese adults (pivotal Phase 3): CSPC states the product significantly reduced body weight compared with placebo; no figures released. The announcement does not report the co-primary proportion with at least 5% weight loss (CSPC announcement, 13 October 2025).
EfpeglenatidePhase 3PeptideGLP-1 receptorReliable signal
NCT06174779: Percent change in body weight from baseline at Week 40: -9.75% (efpeglenatide/HM11260C) vs -0.95% (placebo); least-squares mean difference -8.13 percentage points, statistically significant
ElecoglipronPhase 3Small moleculeGLP-1 receptorReliable signalNo reviewed efficacy summary in this indication
EloralintidePhase 3PeptideAmylin receptorReliable signal
NCT06230523: Body weight, percent change from baseline at Week 48: eloralintide 1 mg -9.4%, 3 mg -12.4%, 6 mg -17.6%, 9 mg -20.1%, 6/9 mg -19.9% and 3/6/9 mg -16.5% vs placebo -0.4%.
EnicepatidePhase 3PeptideGLP-1 receptor, GLP-1/GIP receptor (dual)Reliable signal
NCT06525935: Placebo-adjusted weight loss at Week 48 (efficacy estimand), 24 mg CT-388: 22.5% (p<0.001); treatment-regimen estimand: 18.3% (p<0.001)
HDM1002Phase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
HDM1005Phase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
LenbelintidePhase 3PeptideAmylin receptorPartial signalNo reviewed efficacy summary in this indication
Maridebart Cafraglutide (MariTide)Phase 3PeptideGLP-1R agonist; GIPR antagonistReliable signal
NCT05669599: Primary endpoint percent change in body weight baseline to week 52 (treatment policy estimand): -12.3% to -16.2% across doses vs -2.5% placebo (obesity cohort); -8.4% to -12.3% vs -1.7% placebo (obesity-diabetes cohort)
MazdutidePhase 3PeptideGLP-1/glucagon receptor (dual)Reliable signal
NCT05607680: Co-primary 1, percent change in body weight from baseline to week 32 (treatment-policy estimand): mazdutide 4 mg -10.09% (95% CI -11.15 to -9.04), 6 mg -12.55% (95% CI -13.64 to -11.45) vs placebo +0.45% (95% CI -0.61 to 1.52); P<0.001 for both doses vs placebo, met. Co-primary 2, weight reduction of at least 5% at week 32: 73.9% (4 mg) and 82.0% (6 mg) vs 10.5% (placebo); P<0.001 for both doses vs placebo, met.
MDR-001Phase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
MibavademabPhase 3Monoclonal antibodyLeptin receptorPartial signalNo reviewed efficacy summary in this indication
OlatorepatidePhase 3PeptideGLP-1/GIP receptor (dual)Reliable signal
NCT06839664: Co-primary endpoints met at Week 48: up to 19.3% mean weight loss with olatorepatide from baseline (dose range 5/10/15mg); up to 97.2% of participants achieved ≥5% weight loss, statistically significant vs placebo.
PetrelintidePhase 3PeptideAmylin receptor, Amylin/calcitonin receptor (dual)Partial signal
NCT06662539: Primary endpoint met: statistically significant weight reduction vs placebo at week 28 in all five dose arms; up to 10.7% mean reduction at week 42 vs 1.7% with placebo (ZUPREME-1, 2026-03-05).
RAY1225Phase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
RetatrutidePhase 3PeptideGLP-1/GIP/glucagon receptor (triple)Partial signal
NCT05929079: Primary endpoint, percent change in body weight from baseline to week 80 (treatment-regimen estimand): retatrutide 9 mg -16.8% and 12 mg -18.8% vs placebo -5.1%; treatment differences -11.8% (95% CI -13.7 to -9.8) and -13.8% (95% CI -15.8 to -11.8); p<0.0001 for both, met. Key secondary, 4 mg vs placebo: -11.9% vs -5.1% (difference -6.9%, 95% CI -8.7 to -5.1; p<0.0001). The registered AHI primary in the sleep apnea subset is not reported in the paper abstract.
NCT05931367: Co-primary 1, WOMAC pain subscale change to week 68 (treatment-regimen estimand): retatrutide 9 mg -4.0 points (-67.2%), 12 mg -3.7 points (-62.6%) vs placebo -2.1 points (-35.1%); statistically significant for each dose per the sponsor (p not printed), met. Co-primary 2, percent change in body weight to week 68: 9 mg -20.0%, 12 mg -23.7% vs placebo -4.6%; statistically significant for each dose per the sponsor (p not printed), met.
RibupatidePhase 3PeptideGLP-1/GIP receptor (dual)Reliable signal
NCT06396429: Mean weight loss at Week 48 (treatment policy estimand): up to 17.7% with HRS9531 (16.3 percentage points placebo-adjusted); up to 88.0% of HRS9531-treated participants achieved at least 5% weight loss
Safiglipron (HRS-7535)Phase 3Small moleculeGLP-1 receptorReliable signal
NCT06904105: Percent body-weight change at week 44, treatment-policy estimand (prespecified primary): -8.0% (120 mg) and -9.8% (180 mg) vs -2.4% placebo, superiority stated as met (no p-value given). Proportion with at least 5% weight loss at week 44 (registry primary): 58.6% (120 mg) and 68.2% (180 mg); placebo rate and significance not reported.
SurvodutidePhase 3PeptideGLP-1/glucagon receptor (dual)Partial signal
NCT06066515: Percentage change in body weight from baseline to Week 76 (SYNCHRONIZE-1, primary analysis, treatment-regimen estimand): -13.0% survodutide 6.0 mg and -12.2% 3.6 mg vs -5.4% placebo; body weight reduction of at least 5%: 71.9% and 72.6% vs 46.3% (P<0.001 for all comparisons with placebo).
NCT06066528: Percentage change in body weight from baseline to Week 76 (SYNCHRONIZE-2, primary analysis, treatment-regimen estimand): -9.8% survodutide 6.0 mg and -8.2% 3.6 mg vs -3.9% placebo; body weight reduction of at least 5%: 64.5% and 57.6% vs 35.1% (P<0.001 for all comparisons with placebo).
TesofensinePhase 3Small moleculeNoradrenaline/dopamine/serotonin reuptakeReliable signal
NCT00394667: After 24 weeks, mean weight loss with diet and placebo was 2.0%, while tesofensine doses produced significantly greater reductions of 4.5%, 9.2% and 10.6% respectively.
UBT251Phase 3PeptideGLP-1/GIP/glucagon receptor (triple)not yet gradedNo reviewed efficacy summary in this indication
VCT220Phase 3Small moleculeGLP-1 receptorPartial signal
NCT06939296: Primary endpoint met: 52-week weight loss about 12.2% and 12.4% vs 1.3% with placebo (2026-05-18).
NCT07011797: Phase 2 trial, explicitly named as NCT07011797: primary endpoints met, up to 11.5% weight loss at 36 weeks with CX11 (oral GLP-1 receptor agonist), ongoing weight loss without plateau; gastrointestinal AEs the most common safety finding.
VK2735Phase 3PeptideGLP-1/GIP receptor (dual)Reliable signal
NCT06828055: Primary endpoint (mean % body weight change from baseline at 13 weeks): up to -12.2% with oral VK2735 vs -1.3% placebo; placebo-adjusted -10.9%, p<0.0001
ZenagamtidePhase 3PeptideGLP-1/amylin receptor (dual)Weak signal
NCT06064006: Primary outcome, safety (number of treatment-emergent adverse events; no formal efficacy test). Secondary endpoint, estimated mean bodyweight change vs placebo: -24.3% vs -1.1% at week 36 (60 mg), -22.0% vs 1.9% (20 mg, week 36), -16.2% vs 2.3% (5 mg, week 28), -9.7% vs 2.0% (1.25 mg, week 20); p<0.0001 (Parts A-D), p=0.0003 (Part E) (Lancet 2025).
ZovaglutidePhase 3PeptideGLP-1 receptorReliable signal
NCT07020884: Percentage change in body weight from baseline at 24 weeks: -10.6% (80mg monthly), -13.8% (160mg monthly), -12.5% (80mg biweekly), -14.4% (160mg biweekly) vs -2.4% (placebo); p<0.0001.
Efsubaglutide AlfaPhase 2/3Protein / enzyme therapeuticGLP-1 receptorPartial signal
NCT06732960: Efsubaglutide Alfa produced a mean weight reduction of 7.16% (95% CI: -8.08 to -6.24) versus 0.86% with placebo. Overall, 82.5% of Efsubaglutide-treated participants achieved >=5% weight loss (vs. 0% placebo).
ABBV-295Phase 2PeptideAmylin receptorWeak signalFeatured results are safety only in this race
Apitegromab (Isembyld)Phase 2Monoclonal antibodyMyostatin (pro/latent form)Partial signal
NCT06445075: Change from baseline in total Lean Body Mass at 24 weeks: -1.6 kg (-3.4 lbs) with apitegromab+tirzepatide vs -3.5 kg (-7.6 lbs) with placebo+tirzepatide; difference 1.9 kg (4.2 lbs) less lean-mass loss with apitegromab, i.e. 54.9% relative preservation (p=0.001).
ARD-101Phase 2Small moleculeBitter taste receptor (gut)Partial signal
NCT05121441: General-obesity Phase 2 (n=20): ARD-101 produced a 2.51-fold greater reduction in hunger rating (Control of Eating Questionnaire) vs placebo; p=0.015
AT-7687Phase 2PeptideGIPR antagonistnot yet gradedNo reviewed efficacy summary in this indication
AZD9550Phase 2PeptideGLP-1/glucagon receptor (dual)Partial signalNo reviewed efficacy summary in this indication
BGM1812Phase 2PeptideAmylin/calcitonin receptor (dual)Weak signal
NCT07224399: Placebo-adjusted weight loss 0.2% to 9.2% (LS mean) across dose groups (0.3 to 7.2 mg once weekly for 1 to 4 weeks); no serious adverse events (sponsor-reported, 7 August 2026)
BI 3034701Phase 2PeptideGLP-1/GIP/NPY2 receptor (triple)Weak signalNo reviewed efficacy summary in this indication
BimagrumabPhase 2Monoclonal antibodyActivin/myostatin type II receptorPartial signal
NCT05616013: Change From Baseline in Body Weight at Week 48 (Baseline, Week 48): 30 mg/kg Bimagrumab -9.25 kilogram (kg) (Standard Error 1.33) | 10 mg/kg Bimagrumab + 1.0 mg Semaglutide -12.73 kilogram (kg) (Standard Error 1.29) | 10 mg/kg Bimagrumab + 2.4 mg Semaglutide -14.31 kilogram (kg) (Standard Error 1.34) | 30 mg/kg Bimagrumab + 1.0 mg Semaglutide -13.86 kilogram (kg) (Standard Error 1.29) | 30 mg/kg Bimagrumab + 2.4 mg Semaglutide -17.79 kilogram (kg) (Standard Error 1.29) vs Placebo + 1.0 mg Semaglutide -9.76 kilogram (kg) (Standard Error 1.25) | Placebo + 2.4 mg Semaglutide -14.24 kilogram (kg) (Standard Error 1.17)
Bremelanotide (Vyleesi)Phase 2PeptideMC4RReliable signal
NCT06565611: BMT-801 study (NCT06565611): weight reduction 4.4% (bremelanotide + tirzepatide) vs 1.6% (placebo); p<0.0001.
DapiglutidePhase 2PeptideGLP-1/GLP-2 receptor (dual)Partial signal
NCT05788601: NCT05788601, primary endpoint (% change in body weight, baseline to week 12): 6 mg dapiglutide vs placebo, difference −2.1%; p=0.076. missed
ECC4703Phase 2—Thyroid hormone receptor beta (THRβ)not yet gradedNo reviewed efficacy summary in this indication
Ecnoglutide (VRB-101)Phase 2PeptideGLP-1 receptorPartial signalNo reviewed efficacy summary in this indication
EnobosarmPhase 2Small moleculeAndrogen receptor (selective)Partial signal
NCT06282458: Change in total lean body mass at 16 weeks (day 112), enobosarm+semaglutide vs placebo+semaglutide: 71% relative reduction in lean mass loss (p=0.002); 27% greater fat loss vs control
ERX1000Phase 2Small moleculeLeptinWeak signalNo reviewed efficacy summary in this indication
Garetosmab (Pasatru)Phase 2Monoclonal antibodyActivin Anot yet gradedNo reviewed efficacy summary in this indication
HM15275Phase 2PeptideGLP-1/GIP/glucagon receptor (triple)Weak signalFeatured results are safety only in this race
HRS-4729Phase 2PeptideGLP-1/GIP/glucagon receptor (triple)Weak signalFeatured results are safety only in this race

Large race: only the 60 furthest-along competitors are listed; 58 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Xenical (orlistat) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (4)
August 2027 (2)
Phase 2Type 1 HyperlipoprotenemiaRecruiting
Est. primary completion 2027-08-01 · NCT05816343 · CT.gov ↗
What to watch
Phase 4ObesityNot yet recruiting
Est. primary completion 2027-08-31 · NCT07301437 · CT.gov ↗
What to watch
September 2027 (1)
Phase 2Endometrial Neoplasms, Endometrial Cancer, Atypical Endometrial Hyperplasia, Progestin ResistanceNot yet recruiting
Est. primary completion 2027-09 · NCT07714070 · CT.gov ↗
What to watch
November 2027 (1)
Early phase / not applicableObesityNot yet recruiting
Est. primary completion 2027-11-09 · NCT07326839 · CT.gov ↗
What to watch

See the full readout calendar ↗